NEW YORK (GenomeWeb) – Canadian RNAi drug developer Tekmira Pharmaceuticals has announced that it has agreed to merge with US-based OnCore Biopharma to create a new company focused on an oral cure for hepatitis B virus infection.

As a result of the transaction, which is expected to close in the first half of this year, Tekmira will shift away from being a pure-play RNAi drug firm aiming to use the gene-silencing technology to treat multiple different diseases to a company focused on developing multiple technologies against a single indication.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A draft bill released by the US House of Representatives appropriations committee would increase the 2019 National Institutes of Health budget by 3 percent.

Bloomberg looks into privacy issues raised by law enforcement's use of genetic genealogy sites.

NBC News reports on the Earth BioGenome Project, which aims to sequence all eukaryotic life on Earth.

In Science this week: environmental DNA can help in studies of marine animals, and more.